Financial Data and Key Metrics Changes - Revenue in Q4 2022 decreased by 10.7% to $337.2 million from $377.8 million in Q4 2021 [60] - Net income in Q4 2022 was $26.5 million, or $2.41 per diluted share, while on a non-GAAP adjusted basis, net income increased by 19.4% year-over-year to $40.6 million [42][60] - SG&A expenses decreased by 13.1% to $200.9 million, reflecting lower coach compensation and internal labor expenses [19] - Adjusted gross margin compression of 80 basis points in Q4 was primarily due to inflation, with expectations for price increases to positively impact margins in 2023 [5] Business Line Data and Key Metrics Changes - The number of active earning OPTAVIA Coaches was approximately 60,900, an increase of 1.8% from Q4 2021, but Coach productivity declined both sequentially and year-over-year [60][29] - Average revenue per active earning OPTAVIA Coach for Q4 was $5,538, a year-over-year decline of 12.4% [60] Market Data and Key Metrics Changes - Customer retention levels have returned to historical norms, but customer acquisition remains pressured due to changes in purchasing behavior and social media algorithms [6][28] - The company is focusing on enhancing customer acquisition programs to improve engagement and retention [9][11] Company Strategy and Development Direction - The company is implementing initiatives to improve customer acquisition and optimize the tenure mix, which is crucial for growth [7][11] - A commitment to health business program was launched to align the coach network around customer acquisition [10] - The company aims to maintain operational effectiveness while leveraging investments to deliver high profitability rates even in inflationary environments [13] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by macroeconomic conditions and changing consumer behavior, impacting customer acquisition [22][28] - There is confidence in the ability to navigate the new business environment and achieve long-term growth targets of 15% [64][40] - Management is closely monitoring the impact of new weight loss drugs and increased competition in the wellness space [96][97] Other Important Information - The company declared a quarterly cash dividend of $17.9 million, or $1.64 per share, representing a 15.5% increase compared to the previous year [21] - The financial position remains strong with $87.7 million in cash and no interest-bearing debt as of December 31, 2022 [63] Q&A Session Summary Question: What metrics are being monitored for annual guidance? - Management is focused on customer acquisition metrics, which have not yet returned to historical norms, impacting guidance [71][72] Question: Are coaches able to run their own promotions? - Yes, coaches can run their own promotions through a system that allows them to manage health credits for new client acquisition [79][80] Question: What is the outlook for gross margins in 2023? - Gross margins are expected to be impacted in Q1 due to promotional programs, but long-term targets remain achievable [90][81] Question: How is the company addressing competition from new weight loss drugs? - Management is monitoring the situation closely but has not seen significant impact from these drugs yet [96][97]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from____________to____________. Commission file number: 001-31573 Medifast, Inc. (Exact name of registrant as specified in its charter) | Delaware | 13-3714405 | | ...

Medifast, Inc. (NYSE:MED) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Reed Anderson - ICR Daniel Chard - Executive Chairman & CEO James Maloney - CFO Conference Call Participants Christina Xue - D.A. Davidson Operator Good day, and welcome to the Medifast Third Quarter 2022 Earnings Conference Call. [Operator Instructions]. I would now like to turn the conference over to Reed Anderson with ICR. Please go ahead. Reed Anderson Good afternoon, and welcome to Medifast's Thi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ to ________. Commission File Number: 001-31573 Medifast, Inc. (Exact name of registrant as specified in its charter) | Delaware | 13-371440 ...

Medifast, Inc. (NYSE:MED) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Reed Anderson - ICR, Investor Relations Dan Chard - Chairman & Chief Executive Officer Jim Maloney - Chief Financial Officer Conference Call Participants Chris Neamonitis - Jefferies Operator Good afternoon. And welcome to Medifast Second Quarter 2022 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ to ________. Commission File Number: 001-31573 Medifast, Inc. (Exact name of registrant as specified in its charter) | Delaware | 13-3714405 | | ...

Call Start: 16:30 January 1, 0000 5:09 PM ET Medifast, Inc.???s (NYSE:MED) Q1 2022 Earnings Conference Call May 2, 2022, 4:30 PM ET Company Participants Dan Chard - Chairman and CEO Jim Maloney - Chief Financial Officer Conference Call Participants Chris Neamonitis - Jefferies Linda Bolton Weiser - D.A. Davidson Doug Lane - Lane Research Operator Good afternoon. And welcome to Medifast First Quarter of 2022 Earnings Conference Call. On the call with me today are Dan Chard, Chairman and Chief Executive Offic ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ to ________. Commission File Number: 001-31573 100 International Drive Baltimore, Maryland 21202 Telephone Number: (410) 581-8042 (Address of P ...

Medifast, Inc. (NYSE:MED) Q4 2021 Earnings Conference Call February 23, 2022 4:30 PM ET Company Participants Reed Anderson ??? Investor Relations-ICR, Inc. Dan Chard ??? Chairman and Chief Executive Officer Jim Maloney ??? Chief Financial Officer Conference Call Participants Steph Wissink ??? Jefferies Linda Bolton Weiser ??? D.A. Davidson Doug Lane ??? Lane Research Operator Good day, and welcome to the Medifast Fiscal Fourth Quarter and Full Year 2021 Earnings Conference Call. All participants will be in ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from____________to____________. Commission file number: 001-31573 Medifast, Inc. (Exact name of registrant as specified in its charter) | Delaware | 13-3714405 | | ...